PharmVar GeneFocus: CYP2C9
| dc.contributor.author | Sangkuhl, Katrin | |
| dc.contributor.author | Claudio‐Campos, Karla | |
| dc.contributor.author | Cavallari, Larisa H. | |
| dc.contributor.author | Agundez, Jose A.G. | |
| dc.contributor.author | Whirl‐Carrillo, Michelle | |
| dc.contributor.author | Duconge, Jorge | |
| dc.contributor.author | Del Tredici, Andria L. | |
| dc.contributor.author | Wadelius, Mia | |
| dc.contributor.author | Rodrigues Botton, Mariana | |
| dc.contributor.author | Woodahl, Erica L. | |
| dc.contributor.author | Scott, Stuart A. | |
| dc.contributor.author | Klein, Teri E. | |
| dc.contributor.author | Pratt, Victoria M. | |
| dc.contributor.author | Daly, Ann K. | |
| dc.contributor.author | Gaedigk, Andrea | |
| dc.contributor.department | Medical and Molecular Genetics, School of Medicine | en_US |
| dc.date.accessioned | 2022-02-08T21:59:32Z | |
| dc.date.available | 2022-02-08T21:59:32Z | |
| dc.date.issued | 2021-09 | |
| dc.description.abstract | The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the CYP2C9 gene locus impacts the metabolism or bioactivation of many clinically important drugs including NSAIDs, phenytoin, anti-diabetic agents and angiotensin receptor blocker. Variable CYP2C9 activity is of particular importance regarding efficacy and safety of warfarin and siponimod as indicated in their package inserts. This GeneFocus provides a comprehensive overview and summary of CYP2C9 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC). | en_US |
| dc.eprint.version | Author's manuscript | en_US |
| dc.identifier.citation | Sangkuhl, K., Claudio-Campos, K., Cavallari, L. H., Agundez, J. a. G., Whirl-Carrillo, M., Duconge, J., Tredici, A. D., Wadelius, M., Botton, M. R., Woodahl, E. L., Scott, S. A., Klein, T. E., Pratt, V. M., Daly, A. K., & Gaedigk, A. (2021). PharmVar GeneFocus: CYP2C9. Clinical Pharmacology & Therapeutics, 110(3), 662–676. https://doi.org/10.1002/cpt.2333 | en_US |
| dc.identifier.issn | 0009-9236, 1532-6535 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/27733 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Wiley | en_US |
| dc.relation.isversionof | 10.1002/cpt.2333 | en_US |
| dc.relation.journal | Clinical Pharmacology & Therapeutics | en_US |
| dc.rights | Publisher Policy | en_US |
| dc.source | Author | en_US |
| dc.subject | Pharmacogene Variation Consortium | en_US |
| dc.subject | PharmVar | en_US |
| dc.subject | Genetic variation | en_US |
| dc.subject | CYP2C9 gene | en_US |
| dc.title | PharmVar GeneFocus: CYP2C9 | en_US |
| dc.type | Article | en_US |